Woodline Partners LP Increases Stock Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Woodline Partners LP boosted its holdings in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 8.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 652,421 shares of the biotechnology company's stock after buying an additional 51,358 shares during the period. Woodline Partners LP owned approximately 0.72% of Rocket Pharmaceuticals worth $8,201,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in RCKT. Wellington Management Group LLP increased its holdings in shares of Rocket Pharmaceuticals by 24.5% during the fourth quarter. Wellington Management Group LLP now owns 13,995,177 shares of the biotechnology company's stock valued at $175,919,000 after acquiring an additional 2,753,033 shares in the last quarter. Vanguard Group Inc. grew its position in Rocket Pharmaceuticals by 18.8% during the 4th quarter. Vanguard Group Inc. now owns 6,577,595 shares of the biotechnology company's stock worth $82,680,000 after purchasing an additional 1,040,655 shares during the last quarter. Janus Henderson Group PLC increased its stake in Rocket Pharmaceuticals by 111.0% during the 4th quarter. Janus Henderson Group PLC now owns 4,004,039 shares of the biotechnology company's stock valued at $50,343,000 after purchasing an additional 2,106,699 shares in the last quarter. Suvretta Capital Management LLC purchased a new position in shares of Rocket Pharmaceuticals in the fourth quarter worth $32,267,000. Finally, Geode Capital Management LLC raised its holdings in shares of Rocket Pharmaceuticals by 8.4% in the fourth quarter. Geode Capital Management LLC now owns 1,752,975 shares of the biotechnology company's stock worth $22,041,000 after buying an additional 135,109 shares during the last quarter. 98.39% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently issued reports on RCKT. Wedbush reissued an "outperform" rating and issued a $32.00 target price on shares of Rocket Pharmaceuticals in a research report on Friday, May 16th. BMO Capital Markets began coverage on Rocket Pharmaceuticals in a report on Wednesday, March 12th. They issued an "outperform" rating and a $50.00 price objective on the stock. Canaccord Genuity Group reduced their price objective on Rocket Pharmaceuticals from $36.00 to $34.00 and set a "buy" rating for the company in a research note on Monday, May 12th. Needham & Company LLC reiterated a "buy" rating and issued a $42.00 target price on shares of Rocket Pharmaceuticals in a research report on Wednesday, April 9th. Finally, The Goldman Sachs Group reduced their price target on shares of Rocket Pharmaceuticals from $15.00 to $13.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $37.73.

Rocket Pharmaceuticals Price Performance

Shares of NASDAQ RCKT opened at $6.56 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 6.05 and a quick ratio of 6.05. The stock has a market capitalization of $700.52 million, a price-to-earnings ratio of -2.39 and a beta of 1.02. The firm's 50 day simple moving average is $6.76 and its 200-day simple moving average is $10.04. Rocket Pharmaceuticals, Inc. has a 12 month low of $4.55 and a 12 month high of $26.98.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.58) by $0.02. During the same quarter in the previous year, the company earned ($0.66) EPS. Analysts expect that Rocket Pharmaceuticals, Inc. will post -2.83 EPS for the current year.

Insider Transactions at Rocket Pharmaceuticals

In other news, CFO Aaron Ondrey sold 7,489 shares of the business's stock in a transaction that occurred on Friday, April 4th. The stock was sold at an average price of $5.29, for a total value of $39,616.81. Following the completion of the sale, the chief financial officer now directly owns 129,650 shares in the company, valued at $685,848.50. The trade was a 5.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Gaurav Shah bought 20,000 shares of Rocket Pharmaceuticals stock in a transaction dated Thursday, April 10th. The shares were acquired at an average cost of $5.08 per share, with a total value of $101,600.00. Following the completion of the purchase, the chief executive officer now owns 792,680 shares in the company, valued at approximately $4,026,814.40. This trade represents a 2.59% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 24.76% of the company's stock.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.